Cited by 82Pancreatic function and diabetesDiabetes and associated disordersEndoplasmic Reticulum Stress and Disease

Anti-proliferative effect of pro-inflammatory cytokines in cultured β cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide -1

Open access
Blandino-Rosano, M, Perez-Arana, G, Mellado-Gil, J M, Segundo, C, Aguilar-Diosdado, M·2008·Journal of Molecular Endocrinology

Abstract

Pancreatic β-cell homeostasis is a balance between programmed cell death (apoptosis) and regeneration. Although autoimmune diabetes mellitus type 1 (DM1) is the most-studied cause of β-cell mass loss by pro-inflammatory cytokine-induced apoptosis, influences of a pro-inflammatory environment on β-cell regenerative response have been poorly studied. In this study, we assess the anti-proliferative effect of pro-inflammatory cytokines and glucose concentration on rat pancreatic β cells and the potential protective role of glucagon-like peptide (GLP-1). Apoptotic and proliferating islet cells were stained using the DeadEnd Fluorimetric TUNEL System and 5-bromo-2′-deoxyuridine label respectively, in the presence–absence of varying concentrations of glucose, pro-inflammatory cytokines, and GLP-1. The potential signaling pathways involved were evaluated by western blot. Considerable anti-proliferative effects of pro-inflammatory cytokines interleukin (IL)-1β, interferon (IFN)-γ, and tumour necrosis factor-α (TNF-α) were observed. The effects were synergistic and independent of glucose concentration, and appeared to be mediated by the inhibition of extracellular signal-regulated kinase 1/2 (ERK1/2) activation, the signaling pathway involved in β-cell replication. GLP-1 completely reversed the cytokine-induced inhibition of ERK phosphorylation and increased β-cell proliferation threefold in cytokine-treated cultures. While pro-inflammatory cytokines reduced islet cell ERK1/2 activation and β-cell proliferation in pancreatic islet culture, GLP-1 was capable of reversing this effect. These data suggest a possible pharmacological application of GLP-1 in the treatment of early stage DM1, to prevent the loss of pancreatic β cells as well as to delay the development of overt diabetes.

Integrity signals

Registry

Crossref · 10.1677/jme-07-0154

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • GLP-1-based therapies show anti-inflammatory effects on the liver, vascular system including aorta and vein endothelial cells, brain, kidney, lung, testis, and skin by reducing the production of inflammatory cytokines and infiltration of immune cells in the tissues.

    “emerging data suggest that GLP-1-based therapies also showed anti-inflammatory effects on the liver, vascular system including aorta and vein endothelial cells, brain, kidney, lung, testis, and skin by reducing the production of inflammatory cytokines and infiltration of immune cells in the tissues [17, 21–25].”

Cites

Flagged first, then by citations

1 of the 61 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Blandino-Rosano, M., Perez-Arana, G., Mellado-Gil, J. M., Segundo, C., & Aguilar-Diosdado, M.
Affiliations
Hospital Universitario Puerta del Mar (ES)
Venue
Journal of Molecular Endocrinology
Published
2008-05-15
Volume
41
Issue
1
Pages
35-44
ISSN
  • 0952-5041 (ISSN-L)
  • 1479-6813
OpenAlex
W2160357177
Cited by
82
References
61
Citations by year
2025: 1 · 2024: 2 · 2023: 2 · 2022: 6 · 2021: 2 · 2019: 3 · 2018: 1 · 2017: 7 · 2016: 4 · 2015: 4 · 2014: 7 · 2013: 10 · 2012: 8
FWCI
8.80
Type
journal article
Language
en
Open access
Locations
  • Journal of Molecular Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
Keywords
inflammatory cytokines, beta-cell proliferation, glucagon-like peptide-1, ERK signaling, beta-cell apoptosis, type 1 diabetes, IL-1β, interferon-gamma, TNF-α, glucose, pancreatic islets, beta cell regeneration, ERK1/2 phosphorylation
MeSH terms
Animals, Cells, Cultured, Glucose, Male, Cytokines, Rats, Wistar, Inflammation Mediators, Cell Culture Techniques, Mitogen-Activated Protein Kinase 1, MAP Kinase Signaling System, Mitogen-Activated Protein Kinase 3, Cell Proliferation, Insulin-Secreting Cells, Rats, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review